

The FDA just handed BioMarin's achondroplasia monopoly three extra months of breathing room. Ascendis Pharma's once-weekly rival got delayed by a procedural amendment, and in rare disease, timing is everything.
In pharma, three months can feel like three years. And BioMarin just got handed what might be the most valuable gift in rare disease: extra time.
Ascendis Pharma's achondroplasia drug, the one Wall Street has been watching as a serious threat to BioMarin's monopoly, just got pushed back. The FDA bumped the decision date for TransCon CNP (navepegritide) to February 28, 2026. That's three months later than originally expected. The reason? A revised post-marketing study protocol that the FDA classified as a "major amendment."
In plain English: Ascendis submitted updated plans for how it would monitor the drug after approval, and the FDA decided those changes were significant enough to need more review time. It's a procedural delay, not a safety red flag. But in a market where BioMarin's Voxzogo is the only game in town, procedure matters a lot.
Voxzogo has been the sole approved treatment for achondroplasia in children, the most common form of dwarfism, since 2021. It's a daily injection that helps kids grow taller by targeting the biology behind restricted bone growth. More than 5,000 children worldwide have been prescribed it.
The drug posted 20% revenue growth in Q2 2025. Real-world data from France tracked 6,000 patient-years with zero discontinuations. A Japanese study of 63 kids under three showed no treatment-related side effects and no one stopping treatment. When you're the only option and the safety data looks like that, you build a moat.
Think of it like being the only pizza place in a college town. Even if your pizza is just okay, every student knows your name, your number is on every fridge, and the delivery drivers know every dorm. By the time a competitor opens across the street, you've already locked in habits.
That's what BioMarin is doing right now with every extra month it has.
Ascendis isn't showing up with a worse product. In some ways, TransCon CNP looks like an upgrade.
The biggest selling point: . Voxzogo requires a daily shot. For parents giving injections to young children, cutting that from seven needles a week to one is a massive quality-of-life improvement. One analyst described TransCon CNP as "very similar, and more convenient."

Gilead is paying $7.8 billion for a CAR-T therapy the FDA hasn't approved yet, a 68% premium that looks less like confidence and more like a rescue mission. With its existing cell therapy business shrinking, the company is betting everything on a drug that oncologists already prefer over the competition.


Join thousands of biotech professionals who start their day with our free, daily briefing.
The clinical data is compelling too. In the Phase 3 ApproaCH trial, 84 children aged 2 to 11 received either TransCon CNP or placebo. Kids on the drug grew at 5.89 cm per year, compared to 4.41 cm per year on placebo. That's a statistically significant difference of 1.49 cm per year. The effect was even more pronounced in older kids aged 5 to 11, where the treatment difference hit 1.78 cm per year.
Beyond just growing taller, the trial showed improvements in lower limb alignment, spinal canal dimensions, and muscle strength. TransCon CNP works as a long-acting version of C-type natriuretic peptide, essentially a sustained-release formulation that keeps working between doses instead of spiking and fading every day.
On paper, this is a real competitor. On a calendar, it's still stuck in the waiting room.
Rare disease markets don't work like selling cholesterol drugs to millions of people. The patient populations are small. The prescribing physicians are a tight-knit group of specialists. And once a doctor gets comfortable with a drug, once they've figured out the dosing, navigated insurance approvals, and seen results in their patients, switching is a pain.
Every month that Voxzogo operates without competition, BioMarin's sales team is knocking on doors, locking in reimbursement deals, and building relationships with the endocrinologists and geneticists who treat achondroplasia. It's the same reason first apps on your phone are so hard to delete. You've already invested time learning the interface.
BioMarin also isn't standing still on the science. The company expects to share Phase 3 data for Voxzogo in hypochondroplasia, a related skeletal condition, in 2026, with a potential launch in 2027. Analysts have projected peak sales exceeding $5 billion across different indications. That's a company actively expanding its territory while its rival waits for a permission slip.
Let's be clear about what this PDUFA delay is and isn't. It's not the FDA saying no. It's not a safety concern. Ascendis CEO Jan Mikkelsen emphasized continued collaboration with the agency, and the company says it has responded to all outstanding FDA requests.
Major amendment extensions are standard procedure under PDUFA VII, the latest reauthorization of the law that governs FDA review timelines. When a company submits significant new information during the review cycle, the FDA can tack on three months. It happens. The FDA hit its review targets on 97% of applications in 2023, so the machinery generally works on schedule.
But "standard procedure" doesn't mean "no consequences." Three months of delay means three months of investor uncertainty for Ascendis. It means three months where doctors who might have waited for a weekly option decide to start patients on Voxzogo instead. In pediatric medicine, once a child is responding well to a treatment, the bar for switching gets very high. No parent wants to mess with what's working.
The achondroplasia market is getting more interesting, not less. Beyond TransCon CNP, Tyra Biosciences is developing an oral drug called dabogratinib that could eventually challenge both injectable options. Phase 2 trials started in August 2024, so it's still early, but the idea of a pill replacing weekly or daily shots is the kind of thing that keeps both BioMarin and Ascendis up at night.
For now, though, this is a two-horse race where one horse is already running and the other is still in the starting gate. Ascendis has a drug that could genuinely change the treatment experience for thousands of families. But the clock, and the competition, aren't waiting.
BioMarin didn't ask for this three-month gift. But you can bet they're going to use every single day of it.
Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.